Profile data is unavailable for this security.
About the company
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.
- Revenue in USD (TTM)829.25m
- Net income in USD281.59m
- Incorporated2007
- Employees373.00
- LocationHalozyme Therapeutics Inc12390 EL CAMINO REALSAN DIEGO 92130United StatesUSA
- Phone+1 (858) 794-8889
- Fax+1 (302) 655-5049
- Websitehttps://www.halozyme.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Insmed Inc | 305.21m | -749.57m | 3.67bn | 912.00 | -- | -- | -- | 12.03 | -5.35 | -5.35 | 2.17 | -2.24 | 0.2044 | 0.8562 | 8.61 | 334,657.90 | -50.20 | -40.96 | -58.32 | -46.88 | 78.52 | 77.99 | -245.59 | -212.92 | 3.75 | -17.21 | 1.39 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
| Alvotech SA | 93.38m | -551.73m | 3.87bn | 999.00 | -- | -- | -- | 41.43 | -2.40 | -2.40 | 0.4109 | -3.49 | 0.105 | 2.20 | 1.39 | 93,475.48 | -62.04 | -- | -81.72 | -- | -72.26 | -- | -590.83 | -- | 0.4614 | -1.29 | 7.52 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
| Immunovant Inc | 0.00 | -243.45m | 3.99bn | 164.00 | -- | 5.86 | -- | -- | -1.83 | -1.83 | 0.00 | 4.68 | 0.00 | -- | -- | 0.00 | -41.70 | -- | -44.49 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -34.60 | -- | -- | -- |
| Alkermes Plc | 1.66bn | 519.16m | 4.15bn | 2.10k | 8.12 | 3.41 | 6.99 | 2.50 | 3.02 | 2.07 | 9.79 | 7.20 | 0.8114 | 1.38 | 5.28 | 792,097.60 | 25.32 | 1.34 | 33.69 | 1.74 | 84.79 | 83.32 | 31.21 | 2.12 | 2.50 | -- | 0.1947 | 0.00 | 49.61 | 8.74 | 1,665.99 | -- | -7.10 | -- |
| Alpine Immune Sciences Inc | 58.88m | -32.18m | 4.23bn | 142.00 | -- | 11.89 | -- | 71.91 | -0.6827 | -0.6827 | 1.18 | 5.43 | 0.1767 | -- | 210.65 | 414,619.70 | -9.66 | -21.93 | -11.36 | -27.81 | -- | -- | -54.66 | -170.16 | -- | -- | 0.00 | -- | 95.84 | 142.30 | 44.28 | -- | -0.3253 | -- |
| Madrigal Pharmaceuticals Inc | 0.00 | -373.63m | 4.34bn | 376.00 | -- | 10.00 | -- | -- | -19.93 | -19.93 | 0.00 | 20.39 | 0.00 | -- | -- | 0.00 | -74.49 | -62.09 | -97.21 | -74.81 | -- | -- | -- | -- | -- | -- | 0.2217 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
| Krystal Biotech Inc | 50.70m | 10.93m | 4.37bn | 229.00 | 1,730.37 | 5.55 | 258.81 | 86.12 | 0.0885 | 0.0885 | 1.84 | 27.58 | 0.0737 | -- | -- | 221,393.00 | 1.59 | -11.50 | 1.66 | -12.01 | 93.90 | -- | 21.56 | -492.85 | 17.55 | -- | 0.00 | -- | -- | -- | 107.81 | -- | 39.49 | -- |
| Nuvalent Inc | 0.00 | -126.22m | 4.45bn | 92.00 | -- | 6.30 | -- | -- | -2.16 | -2.16 | 0.00 | 10.94 | 0.00 | -- | -- | 0.00 | -20.78 | -- | -21.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.20 | -- | -- | -- |
| Organon & Co | 6.26bn | 1.02bn | 4.76bn | 10.00k | 4.66 | -- | 3.78 | 0.7596 | 3.99 | 3.99 | 24.44 | -0.2738 | 0.5443 | 2.17 | 3.89 | 626,300.00 | 8.89 | 16.53 | 11.64 | 20.97 | 59.84 | 65.12 | 16.33 | 26.79 | 1.09 | 2.31 | 1.01 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
| BridgeBio Pharma Inc | 9.30m | -643.20m | 4.79bn | 550.00 | -- | -- | -- | 515.34 | -3.95 | -3.95 | 0.0572 | -7.73 | 0.0159 | -- | -- | 16,914.54 | -111.72 | -72.44 | -148.01 | -89.72 | 73.71 | 94.41 | -7,021.94 | -1,225.66 | -- | -13.34 | 4.49 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
| Halozyme Therapeutics, Inc. | 829.25m | 281.59m | 4.84bn | 373.00 | 18.07 | 57.63 | 13.30 | 5.84 | 2.11 | 2.11 | 6.18 | 0.6611 | 0.464 | 1.69 | 3.56 | 2,223,199.00 | 15.75 | 18.22 | 16.90 | 21.97 | 76.80 | 79.05 | 33.96 | 39.36 | 5.50 | 139.09 | 0.9471 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
| Apellis Pharmaceuticals Inc | 396.59m | -528.63m | 5.33bn | 702.00 | -- | 27.16 | -- | 13.44 | -4.48 | -4.48 | 3.34 | 1.63 | 0.5121 | 0.5042 | 3.70 | 564,944.40 | -68.26 | -73.88 | -93.25 | -90.03 | 85.25 | -- | -133.29 | -326.49 | 2.50 | -59.78 | 0.6775 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
| Immunitybio Inc | 622.00k | -583.20m | 5.38bn | 628.00 | -- | -- | -- | 8,657.36 | -1.13 | -1.13 | 0.0012 | -0.875 | 0.0014 | -- | 0.246 | 990.45 | -134.71 | -112.76 | -377.77 | -316.07 | -- | -- | -93,866.88 | -37,700.74 | -- | -2.08 | 3.32 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
| Blueprint Medicines Corp | 249.38m | -506.98m | 5.74bn | 655.00 | -- | 42.76 | -- | 23.01 | -8.37 | -8.37 | 4.12 | 2.14 | 0.2079 | 0.3354 | 6.23 | 380,732.80 | -42.26 | -29.92 | -50.67 | -34.06 | 96.58 | -- | -203.30 | -116.65 | 3.66 | -25.88 | 0.6465 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
Data as of May 01 2024. Currency figures normalised to Halozyme Therapeutics Inc's reporting currency: US Dollar USD
46.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2023 | 15.61m | 12.28% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 12.88m | 10.14% |
| Artisan Partners LPas of 31 Dec 2023 | 6.69m | 5.27% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 6.48m | 5.10% |
| Snyder Capital Management LPas of 31 Dec 2023 | 3.71m | 2.92% |
| AllianceBernstein LPas of 31 Dec 2023 | 3.46m | 2.73% |
| Macquarie Investment Management Business Trustas of 31 Dec 2023 | 3.28m | 2.58% |
| Geode Capital Management LLCas of 31 Dec 2023 | 2.92m | 2.30% |
| GW&K Investment Management LLCas of 31 Dec 2023 | 2.23m | 1.75% |
| TD Asset Management, Inc.as of 31 Dec 2023 | 1.98m | 1.56% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
